- Home
- ZENV vs OTLK Comparison
ZENV vs OTLK Comparison
Compare ZENV & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZENV | OTLK |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.3M | 38.7M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ZENV | OTLK |
|---|---|---|
| Price | $0.89 | $0.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 33.7K | ★ 13.1M |
| Earning Date | 03-16-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,426,369.00 | $1,413,535.00 |
| Revenue This Year | $12.75 | $1,578.49 |
| Revenue Next Year | N/A | $153.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.80 | N/A |
| 52 Week Low | $0.86 | $0.50 |
| 52 Week High | $2.74 | $3.39 |
Technical Indicators
Market Signals| Indicator | ZENV | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 35.11 | 26.06 |
| Support Level | $0.86 | $0.51 |
| Resistance Level | $1.00 | $0.56 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 26.95 | 14.45 |
Price Performance
Historical ComparisonAbout ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.